MedTrace Logo

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

NCT01537705 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-02-23

No results posted yet for this study

Summary

A clinical outcomes study measuring reduction in pain and numbness experienced in four types of peripheral neuropathy patients during 60 day administration of the an amino acid formulation.

Conditions

  • Diabetic Neuropathy
  • Chemotherapy Induced Neuropathy
  • HIV Neuropathy
  • Trauma Induced Neuropathy

Interventions

DRUG

Neuron012703 (Medical Food)

2 capsules twice daily for sixty days.

Sponsors & Collaborators

  • Targeted Medical Pharma

    lead INDUSTRY

Principal Investigators

  • Gabriel Halperin, DPM · Gabriel Halperin DPM Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01537705 on ClinicalTrials.gov